Drug Topics
NOVEMBER 4, 2024
The FDA has mandated that companies participating in the Opioid Analgesic Risk Evaluation and Mitigation Strategy program provide pre-paid mail-back envelopes for unused or expired opioid medications.
STAT
NOVEMBER 5, 2024
A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing. Beam said the patient succumbed to respiratory failure, deemed to be “likely caused” by a regimen of chemotherapy required to prepare the patient for BEAM-101, a treatment that uses the company’s new, more precise form of CRISPR gene editing called base editing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
NOVEMBER 5, 2024
Using in vitro models, study investigators predict the risk of bone metastasis in breast cancer based on correlations with their in vivo behaviors and potential.
Fierce Healthcare
NOVEMBER 2, 2024
The Centers for Medicare and Medicaid Services (CMS) is moving forward with a 2.9% cut to physician payments in 2025 despite protest from major industry groups. | The Centers for Medicare and Medicaid Services (CMS) is moving forward with a 2.9% cut to physician payments in 2025 despite protest from major industry groups.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
NOVEMBER 1, 2024
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semagluti | Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study. The positive results build on the thesis that GLP-1s could become a foundational piece in the treatment paradigm for the fatty liver disease, according to analysts at William Blair.
Drug Topics
NOVEMBER 4, 2024
Ruth Carrico PhD, DNP, APRN, discussed the importance of annual vaccination and overall health awareness and literacy during the winter flu season.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
NOVEMBER 2, 2024
ASCO is prioritizing the expansion of pharmacist involvement in its organization by recognizing pharmacists' contributions to safety standards, quality improvement initiatives, and certification programs.
Fierce Healthcare
NOVEMBER 3, 2024
Under a final rule issued by the Centers for Medicare and Medicaid Services, outpatient hospital facilities and ambulatory surgical centers will get a 2.9% Medicare pay increase next year, up from | Under a final rule issued by CMS, outpatient hospital facilities and ambulatory surgical centers will get a 2.9% Medicare pay increase next year, up from the 2.6% boost in reimbursement that was floated in the draft rule.
pharmaphorum
NOVEMBER 5, 2024
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.Shares in the company gained almost 24% after it announced that the end of phase 2 meeting with the US regulator had firmed up plans for a phase 3 trial of bitopertin in EPP, as well as the potential for accelerated approval.
Drug Topics
NOVEMBER 5, 2024
Erin Rexroth, director of marketing at NCPA, discusses how smaller pharmacies can compete with large chains when it comes to digital marketing.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
NOVEMBER 4, 2024
Researchers like to say that science is self-correcting, that knowledge is slowly but surely refined by new findings that build on or debunk old ones. But this process is far from perfect and is hampered by sloppy experiments or, in some cases, faked results. A small, tight-knit community of scientific sleuths has been unearthing growing evidence that many studies, including landmark papers published in top journals, contain manipulated images and falsified findings.
Pharmacy Times
OCTOBER 30, 2024
Results indicate that sublingual epinephrine can resolve symptoms, including swelling of the face and throat, associated with oral allergy syndrome in minutes.
Fierce Pharma
NOVEMBER 5, 2024
Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial.
Pharmaceutical Commerce
OCTOBER 31, 2024
With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
NOVEMBER 4, 2024
Ruth Carrico, PhD, DNP, APRN, discussed declining influenza and COVID-19 vaccination rates and how it has created a looming threat for public health officials.
STAT
NOVEMBER 4, 2024
This is Part 5 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. When patents for name brand medicines expire, the price of that medicine drops significantly as generic versions enter the market. Lower prices are good news for patients seeking more affordable medications, but the change can sometimes take a while.
Pharmacy Times
NOVEMBER 4, 2024
The randomized, placebo-controlled RESCUE phase 3 trial assessed clofutriben among individuals with ACTH-dependent endogenous Cushing syndrome.
Fierce Healthcare
OCTOBER 31, 2024
Optum Rx is rolling out a slate of new programs that seek to support independent pharmacies in managing costs and more complex patient needs. | Optum Rx is rolling out a slate of new programs that seek to support independent pharmacies in managing costs and more complex patient needs.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
NOVEMBER 5, 2024
With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta thalassemia, “there has never been a more exciting time to be at Vertex,” c | With its first Casgevy revenues in the books, Vertex lifted its full-year sales outlook as it turns its attention to two product launches in 2025, including an expected new entrant in the pain market.
Drug Topics
NOVEMBER 6, 2024
A recent study found that losing a family member or a friend to COVID-19 within the past year led to higher levels of vaccine acceptance.
STAT
NOVEMBER 5, 2024
In a viral TikTok, a woman in the emergency room shares a message questioning why so many women in their 30s struggle with cancer and infertility, and suggests that birth control’s long-term hormonal disruption is the cause. Another influencer mocks the FDA inserts that accompany birth control, unfolding the long lists of side effects in videos to humorously repurpose them as “blankets” for napping or as tools for helping men grasp the harsh realities their partners face to
Pharmacy Times
OCTOBER 30, 2024
This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.
pharmaphorum
NOVEMBER 5, 2024
Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high. In today’s podcast, web editor Nicole Raleigh speaks with Dr Neal Kassell, chair and founder of the Focused Ultrasound Foundation and previously a neurosurgeon, who created the Foundation in 2006 to improve the lives of millions of people with serious medical disorders by accelerating the development and adoption of focused ult
Fierce Pharma
NOVEMBER 4, 2024
BioNTech reported surprisingly strong sales of its COVID-1 | BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter. Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2.5 billion to €3.1 billion.
Drug Topics
NOVEMBER 5, 2024
“Emrosi has potential to become the best-in-class oral medication to treat the condition,” said the CEO of Journey Medical.
STAT
OCTOBER 31, 2024
Barely 12 years after the publication of the first papers unveiling CRISPR-Cas9, a powerful enzyme for editing DNA, sickle cell patients are now receiving the first approved CRISPR-based medicine, Casgevy. Hundreds of patients with other inherited diseases, cancers, and chronic bacterial and viral infections are enrolled in clinical trials testing other CRISPR treatments.
Pharmacy Times
NOVEMBER 1, 2024
ASHP investigators determined the severity and impact of ongoing drug shortages, with approximately 99% of respondents reporting that they experienced a shortage.
pharmaphorum
NOVEMBER 4, 2024
Outlook Therapeutics' Lytenava is the first ophthalmic formulation of bevacizumab to be cleared for use by NICE for use in the NHS for wet AMD
Fierce Pharma
NOVEMBER 1, 2024
An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry. | An FDA investigation last year into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry.
Drug Topics
NOVEMBER 6, 2024
Researchers compared the issue of drug shortages and supply chain challenges between the US and Canada.
STAT
OCTOBER 31, 2024
Britain’s hardships during World War II famously included weeks of bombing during the Blitz, the mass evacuation of children, and food rationing. That rationing, researchers report, holds cautionary lessons for today on the health impact of consuming sugar early in life. Black-and-white wartime photos capture long queues in the shops when supplies of meat, dairy, sugar, and other food were limited.
Pharmacy Times
NOVEMBER 5, 2024
Less than 16% of high-risk lung cancer individuals have heard or discussed lung cancer screenings with a health care provider.
Med Ed 101
NOVEMBER 3, 2024
There are two agents that are frequently used in alcohol use disorder. Acamprosate and naltrexone have distinct advantages and disadvantages in the treatment of alcohol use disorder. In this article, we will compare the clinical benefits and risks of acamprosate vs naltrexone. What do the guidelines say? Both naltrexone and acamprosate are considered first-line treatments […] The post Acamprosate vs Naltrexone – Clinical Comparison appeared first on Med Ed 101.
Expert insights. Personalized for you.
201 
Let's personalize your content